 Home > Medical News > Medicines Company News > Genting Xinyao's innovative drug for the treatment of metastatic triple-negative breast cancer, gosartuzumab, was included in the priority review category by the National Medical Products Administration

Genting Xinyao's innovative drug for the treatment of metastatic triple-negative breast cancer, gosartuzumab, was included in the priority review category by the National Medical Products Administration

 Last Update: 2021-07-06
 Source: Internet
 Author: User

Tags

breast adenocarcinoma

biofilm removal products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Genting Xinyao, a biopharmaceutical company focusing on the development and commercialization of innovative drugs, is committed to meeting the unmet medical needs of Greater China and other Asian markets.
Sacituzumab govitecan-hziy was included in the priority review varieties
.

The approval to be included in the priority review category was obtained after the company’s announcement on May 17 that the National Medical Products Administration of China has accepted the application for the marketing authorization of gosartuzumab (sacituzumab govitecan-hziy) for biological products.
Another new development
.

Gosartuzumab is used to treat adult patients with locally unresectable advanced or metastatic triple-negative breast cancer (at least one of which is metastatic disease) who has received at least two lines or more of previous treatment

Shi Yang, Chief Medical Officer of Genting Xinyao's Oncology Field, said: "We are very pleased that the National Medical Products Administration has included gosartuzumab in the priority review category
.

The health of patients with metastatic triple-negative breast cancer in China has been seriously affected.

The English trade name of Gosartuzumab is Trodelvy®.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.